I am not such a fan of going it alone. P3 is not much more than...

I am not such a fan of going it alone. P3 is not much more than a re-hash of P2b, just with better dose control. P3 has been de-risked.

A deal now with the appropriate milestone payments can't be that much less valuable than P3/approved stage - certainly from a royalties perspective. If they can't do a deal now I would have concerns about why not, and going alone on P3 might not return much more consider the dilution impacts.

I'm bailing if they go it alone.